NU
Neuren Pharmaceuticals Limited
NURPF · OTC
$16.10 +0.00% (+$0.00)
1M -0.62%
Market Cap $2.85B
P/E Ratio 93.72x
Div. Yield -
ROE 8.96%
Bulios Fair Price
$23.96
48.8% upside
Current Price
$16.1
Undervalued Fair Value Overvalued
According to Bulios Fair Price, NURPF is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Moderate
6/9Valuation
17 /100
Expensive P/B 8.43x
P/S 44.13x
P/E 93.72x
Growth
100 /100
Growing Book val. growth 101.12%
FCF growth 227.14%
EPS growth 455.51%
Profitability
100 /100
Strong FCF margin 193.99%
Op. margin 34.07%
Gross margin 99.96%
Quality
37 /100
Average Asset turnover 0.19x
ROA 8.88%
ROIC 5.09%
Debt
100 /100
Low Current ratio 76.60x
Net debt/EBITDA -0.19x
Debt/Equity 0.00x
Stability
17 /100
Unstable Profitable years 4
EPS volatility 49,454.60%
Beta 1.59x
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about NURPF
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Jonathan Charles Pilcher
Employees
8
Headquarters
Hawthorn East
Upcoming events
15 SEP
Ex-Dividend
Ex-dividend date
07 OCT
Dividend Payment
Payment date
24 FEB
Earnings
Upcoming earnings report